Potential new microbiome therapies for vaginal dsybiosis

NEW ARTICLE SUMMARY

Vaginal dsybiosis and the potential of vaginal microbiome-directed therapeutics.

Published: October 2024

What was studied?

This study investigated current treatment options for vaginal microbiome dysbiosis (and associated conditions such as BV and thrush).

This includes discussing the potential of LBPs, (Live Therapeutic Products). These are treatments containing live microorganisms, often Lactobacillus species, designed to restore microbial balance.

The role of vaginal dysbiosis in gynae concerns

The researchers discuss the role of vaginal dysbiosis (imbalance) in a range of gynaecological conditions such as BV and yeast infections (thrush). These imbalances are often characterised by a reduction in beneficial lactobacilli and an increase in pathogenic microorganisms.

The limitations of current treatments

The article highlights limitations of existing treatment options, which focus on symptom-driven care, rather than underlying microbiome imbalances.

Standard interventions (for conditions like BV & Thrush) include antibiotics and antifungals, which, despite high initial cure rates, can result in recurrence and the development of resistance.

These methods are ineffective at restoring a healthy microbiome, which may contribute to higher recurrence rates.

LBP potential

This research investigated the potential of LBPs, particularly those containing lactobacilli, as intravaginal treatments to modulate the vaginal microbiome and restore balance.

The authors highlight the need for alternative therapies that not only treat infections but also promote a healthy vaginal microbiome, reducing the likelihood of recurrence and resistance.

They also highlight the benefit of targeted therapies, based on microbiome testing, which can tailor treatments to each person’s specific microbiome composition.

Fariba Khonsari